Latent Myofascial Trigger Points Release Therapy for Adult Cough Variant Asthma

Abstract Background:Cough variant asthma (CVA) is a chronic inflammatory airway disease characterized by airway hyper-responsiveness (AHR). However, it’s precise mechanism is not clear yet. The date show that latent myofascial trigger points (MTrPs) can induce autonomic phenomena, such as over secretion, airway hyper-responsiveness, and so on. Therefore, we assumed that latent MTrPs might disrupt the balance between sympathetic and parasympathetic, which might play an essential role in the etiology of CVA.Results:Recurrence rate was lower in the intervention group than the control group (36w, 5.0% vs. 34.5%, P=0.001). There were significant between-group differences in change from baseline to 36 weeks in VAS (5.80±1.20 to 1.70±1.49 and 5.53±1.21 to 3.18±2.04, respectively; 95%CI, -2.00 to -1.00; P=0.001); ACT-scores (12.78±1.86 to 21.38±2.65 and 13.09±1.97 to 18.53±3.00, respectively; 95%CI, 2.00 to 4.00; P<0.001); ACQ5-scores (2.35±0.86 to 0.85±0.55 and 2.38±0.50 to 1.52±0.62, respectively; 95%CI, -1.00 to -0.40; P<0.001); AQLQ-scores (119.65±17.55 to 174.40±18.22 and 126.22±15.58 to 151.69±24.04, respectively; 95%CI, 14.00 to 34.00; P<0.001); Rate of rescue medication used (36w, 5.0% vs. 29.1%, P=0.003). Fewer adverse events were founded between the two groups (7.5% vs. 14.5%, P=0.462). Conclusions:Compared with budesonide-formoterol plus montelukast therapy, latent MTrPs injection therapy provided a long-acting, practical, short treatment course and safety methods for CVA. The findings indicated that latent MTrPs might play a vital role in the pathogenesis of CVA.Clinical Trials Registration: Chinese Clinical Trial Registry, ChiCTR2100044079. Registered 9 March 2021, http://www.chictr.org.cn/index.aspx